332 related articles for article (PubMed ID: 25253844)
1. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
Mabrouk OS; Viaro R; Volta M; Ledonne A; Mercuri N; Morari M
J Neurosci; 2014 Sep; 34(39):12953-62. PubMed ID: 25253844
[TBL] [Abstract][Full Text] [Related]
2. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Marti M; Trapella C; Viaro R; Morari M
J Neurosci; 2007 Feb; 27(6):1297-307. PubMed ID: 17287504
[TBL] [Abstract][Full Text] [Related]
3. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
Marti M; Mela F; Veronesi C; Guerrini R; Salvadori S; Federici M; Mercuri NB; Rizzi A; Franchi G; Beani L; Bianchi C; Morari M
J Neurosci; 2004 Jul; 24(30):6659-66. PubMed ID: 15282268
[TBL] [Abstract][Full Text] [Related]
4. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Mabrouk OS; Marti M; Morari M
Neuroscience; 2010 Mar; 166(1):40-8. PubMed ID: 20006677
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
Mabrouk OS; Volta M; Marti M; Morari M
J Neurochem; 2008 Dec; 107(6):1647-59. PubMed ID: 19094058
[TBL] [Abstract][Full Text] [Related]
6. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Marti M; Trapella C; Morari M
J Neurochem; 2008 Dec; 107(6):1683-96. PubMed ID: 19014386
[TBL] [Abstract][Full Text] [Related]
7. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
[TBL] [Abstract][Full Text] [Related]
8. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
Volta M; Viaro R; Trapella C; Marti M; Morari M
Exp Neurol; 2011 Mar; 228(1):126-37. PubMed ID: 21215744
[TBL] [Abstract][Full Text] [Related]
9. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).
Volta M; Marti M; McDonald J; Molinari S; Camarda V; Pelà M; Trapella C; Morari M
Peptides; 2010 Jun; 31(6):1194-204. PubMed ID: 20307605
[TBL] [Abstract][Full Text] [Related]
11. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
Viaro R; Marti M; Morari M
Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
[TBL] [Abstract][Full Text] [Related]
12. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
Volta M; Mabrouk OS; Bido S; Marti M; Morari M
J Neurochem; 2010 Dec; 115(6):1543-55. PubMed ID: 20950413
[TBL] [Abstract][Full Text] [Related]
13. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.
Viaro R; Sanchez-Pernaute R; Marti M; Trapella C; Isacson O; Morari M
Neurobiol Dis; 2008 Jun; 30(3):430-438. PubMed ID: 18413287
[TBL] [Abstract][Full Text] [Related]
14. The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.
Mabrouk OS; Marti M; Salvadori S; Morari M
Neuroscience; 2009 Dec; 164(2):360-9. PubMed ID: 19729051
[TBL] [Abstract][Full Text] [Related]
15. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
16. Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures.
Bregola G; Zucchini S; Rodi D; Binaschi A; D'Addario C; Landuzzi D; Reinscheid R; Candeletti S; Romualdi P; Simonato M
J Neurosci; 2002 Nov; 22(22):10030-8. PubMed ID: 12427860
[TBL] [Abstract][Full Text] [Related]
17. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
Marti M; Rodi D; Li Q; Guerrini R; Fasano S; Morella I; Tozzi A; Brambilla R; Calabresi P; Simonato M; Bezard E; Morari M
J Neurosci; 2012 Nov; 32(46):16106-19. PubMed ID: 23152595
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
Rutten K; Tzschentke TM; Koch T; Schiene K; Christoph T
Eur J Pharmacol; 2014 Oct; 741():264-71. PubMed ID: 25169429
[TBL] [Abstract][Full Text] [Related]
19. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
Marti M; Mela F; Fantin M; Zucchini S; Brown JM; Witta J; Di Benedetto M; Buzas B; Reinscheid RK; Salvadori S; Guerrini R; Romualdi P; Candeletti S; Simonato M; Cox BM; Morari M
J Neurosci; 2005 Oct; 25(42):9591-601. PubMed ID: 16237164
[TBL] [Abstract][Full Text] [Related]
20. NOP Receptor Ligands and Parkinson's Disease.
Mercatelli D; Pisanò CA; Novello S; Morari M
Handb Exp Pharmacol; 2019; 254():213-232. PubMed ID: 30689087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
